Recordati 주식 가격. REC - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

가격

54.45

( -0.18% )

매수가

53.80

매도가

54.80

거래량

205,911

54.20 일간 변동폭 54.75

46.34 52주 범위 60.50

market_cap

11.182B

전일 종가

54.55

개장가

54.25

최근 거래 시간

54.45

마지막 거래 시간

재정 규모

VWAP

평균 볼륨(3m)

306,651

발행 주식

205,358,104

배당수익률

2.20%

주가수익률

32.27

주당순이익(EPS)

2.03

매출

2.33B

순이익

416.51M

섹터

Pharmaceutical Preparations

산업

Pharmaceutical Preparations

웹사이트

www.recordati.it

본부

Milan, Lombardy, Ita

설립됨

1926

Recordati SpA is listed in the Pharmaceutical Preparations sector of the 이탈리아 증권거래소 with ticker REC. The last closing price for Recordati was 54.55 €. Over the last year, Recordati shares have traded in a share price range of 46.34 € to 60.50 €.

Recordati currently has 205,358,104 shares in issue. The market capitalisation of Recordati is 11.20 € billion. Recordati has a price to earnings ratio (PE ratio) of 32.27.

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE RECORDATI ANNOUNCES EXCLUSIVE...

RECORDATI: TO BE HIGHLIGHTED AT AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY (AACE) ANNUAL MEETING--THE EXPANDED INDICATION FOR ISTURISA® (OSILODROSTAT) FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN ADULT PATIENTS WITH CUSHING'S SYNDROME FOR WHOM

RECORDATI: TO BE HIGHLIGHTED AT AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY (AACE) ANNUAL MEETING--THE EXPANDED INDICATION FOR ISTURISA®...

RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%

RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2...

RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION

RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND €...

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S...

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED...

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5...

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE Milan, 4th October 2024 –...

Recordati Rare Diseases annonce la publication dans The Journal of Clinical Endocrinology & Metabolism des résultats de l’étude de Phase III LINC 4 confirmant l'efficacité et la tolérance d’Isturisa® (osilodrostat)...

L’étude LINC 4 a démontré la supériorité d’Isturisa® (osilodrostat) comparé au placebo pour normaliser le cortisol au cours de la phase de 12...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	1	1.87090739008	53.45	54.75	53.2	191575	53.95704267	DE
4	-0.15	-0.274725274725	54.6	55.2	52.6	224198	53.86585058	DE
12	5.99	12.3607098638	48.46	55.35	47.7	306651	52.58725933	DE
26	1.15	2.15759849906	53.3	60.5	46.34	373415	53.56130725	DE
52	4.3	8.57427716849	50.15	60.5	46.34	310726	52.68833795	DE
156	11.45	26.6279069767	43	60.5	34.52	252682	47.71560132	DE
260	8.28	17.9337231969	46.17	60.5	34.52	264544	47.33491294	DE

REC - Frequently Asked Questions (FAQ)

What is the current Recordati share price?

The current share price of Recordati is 54.45 €

How many Recordati shares are in issue?

Recordati has 205,358,104 shares in issue

What is the market cap of Recordati?

The market capitalisation of Recordati is EUR 11.2B

What is the 1 year trading range for Recordati share price?

Recordati has traded in the range of 46.34 € to 60.50 € during the past year

What is the PE ratio of Recordati?

The price to earnings ratio of Recordati is 32.27

What is the cash to sales ratio of Recordati?

The cash to sales ratio of Recordati is 5.78

What is the reporting currency for Recordati?

Recordati reports financial results in EUR

What is the latest annual turnover for Recordati?

The latest annual turnover of Recordati is EUR 2.33B

What is the latest annual profit for Recordati?

The latest annual profit of Recordati is EUR 416.51M

What is the registered address of Recordati?

The registered address for Recordati is VIA MATTEO CIVITALI 1, MILAN, LOMBARDY, 20148

What is the Recordati website address?

The website address for Recordati is www.recordati.it

Which industry sector does Recordati operate in?

Recordati operates in the PHARMACEUTICAL PREPARATIONS sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
WS3D25Solid World Group spa	0.0139 € (1,444.44%)	174.37k
WMPT25Impianti SpA	0.0983 € (66.89%)	1.06k
1OPENOpendoor Technologies Inc	0.87 € (36.15%)	5.63k
WFCH25Franchetti SPA	1.9498 € (18.17%)	2.1k
1KTOSKratos Defense and Security Solutions Inc	44.62 € (14.97%)	319
HIKAAHaiki SpA	0.0019 € (-48.65%)	2.56M
WEGB26EGlobe SpA	0.0022 € (-29.03%)	100k
WABTGAlfio Bardolla Training Group Spa	0.065 € (-26.80%)	11.61k
WHIK26Haiki Spa	0.043 € (-22.94%)	2.8k
WIVN26iVision Tech SpA	0.37 € (-14.90%)	40.1k
TITTelecom Italia SpA	0.4055 € (-1.07%)	90.32M
ISPIntesa Sanpaolo Spa	4.92 € (-1.37%)	54.83M
SPMSaipem Spa	2.398 € (0.97%)	41.95M
STLAMStellantis NV	8.581 € (-4.71%)	25.33M
BPEBper Banca SPA	7.392 € (-2.04%)	19.19M

fuagf 3 분 전

Filthy politics.

Mountdallas 3 분 전

You love me haha. Yea sure let's hear it

SNPW

fuagf 5 분 전

He would miss Geoffrey. He's still off more than on. Imagine this ex-aussie seeing him as the best ..
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176422009 . Nick Adams.

zerosnoop 6 분 전

The latest PR below reads great MASSIVE ORDER of 400 units for the PROVEN AOT worth in the BILLIONS

https://ir.qsenergy.com/news/press-releases/detail/2064/qs-energy-receives-initial-order-for-multi-year-aot-technology-deployment

QS Energy Receives Initia

QSEP

zerosnoop 7 분 전

OTHER CONSIDERATIONS

QS Energy will earn a share of incremental barrels gained through AOT-enabled flow increases, creating long-term performance-based revenue.

QSEP

zerosnoop 7 분 전

Which country will sign next ? These additional deals could be worth in the billions for the company

EXPANDING GLOBAL PARTNERSHIPS AND FINANCING

This agreement positions Southeast Asia and Africa as leaders in modern crude transport and job creation. The success of this

QSEP

mgland 9 분 전

Unusual but it does happen

zerosnoop 9 분 전

If authorities don't believe the lies & nonsense told by the PAID BASHERS & NAKED SHORT SELLERS, nor do I. The sale of 400 PROVEN AOT units = $2 BILLION deal $$$$$$ is AWESOME news. The PROVEN AOT is a "GAME CHANGER" for the oil industry worldwide.

The manufacturing & production for

QSEP

rbtree 11 분 전

Agreed. But QNC will start to catch up sooner or later.

QNCCF

fuagf 12 분 전

LOL I know the LOL to cover .... bench heroics misplay ploy well. Have been thinking
for a long time, when will Fitzpatrick come through. Hope, maybe, this week.. Good luck.

zerosnoop 13 분 전

Wow, the PAID BASHERS & NAKED SHORT SELLERS are panicking big time in the boiler room. They need to make up new stories & tell more lies. Intelligent investors with a high IQ don't believe lies & nonsense told by uneducated fools & grubs.

I can't wait for the SHORT SQUEEZE when the co

QSEP

rbtree 14 분 전

I do agree that this, only because it does have sales, might be worth closer to 05....

But it's worth what people are willing to pay for it, and with few followers and close to zero interest...it may never recover.

KEGS

Juststoppingby 14 분 전

Currently, the top priority for Coretec is to bring itself up to date with the SEC.
Commercialize Endurion battery technology.
I don't see why they can't give us some update on Endurion, in the meantime.

CRTG

fuagf 15 분 전

Like the thought.

Shev11 15 분 전

This will probably continue to bleed until the deal is finalized. Until then unlimited 1s for everybody. Been here for like 2 years.. What's another 3months meh. They don't necessarily need 3 months, they can still get it done within it. Heck they might even surprise us.. Won't that be something.

GTCH

shoondale 17 분 전

So serious they aren't funding HAD either and remaining anonymous?
https://media.tenor.com/HpeA89dsG34AAAAM/bullshit.gif
Maybe any new partners are actually serious about business

MWWC

rbtree 18 분 전

Not quite. There are several of us here that would never have bought this junk...or any similar OTC dark non-filer, let alone think about it.

KEGS

Zorax 18 분 전

The brics group of countries have been the biggest buyers and stock pilers of gold since cheeto mussolini's first rodeo.
It's why gold is so high right now because countries are hording gold right now. They are hedging for a future cheeto destroyed dollar. Which cheeto actually wants to inser

handsomehank 19 분 전

Pie Holes United…are you trying to make ihub great again? Such patriots lol.

Luckily those that choose to see the glass half full are walking on 🌈 and riding our 🦄 into the moonlight 🌖

LQMT

DrivenByPain 19 분 전

Wrong Xu !

SGDHD

Genz2 20 분 전

https://insideevs.com/news/717341/tesla-cheapest-repair-maintenance-costs/

IMO, this article should be re-posted in the U.S., Europe and China on X news!!! It is something that every potential buyer of a car should see!!! Unfortunately, a lot of people go out and buy a car without e

TSLA

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Recordati SpA (REC)

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

주요 통계 및 세부정보

Recordati SpA 정보

REC 최신 뉴스

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

RECORDATI: TO BE HIGHLIGHTED AT AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY (AACE) ANNUAL MEETING--THE EXPANDED INDICATION FOR ISTURISA® (OSILODROSTAT) FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN ADULT PATIENTS WITH CUSHING'S SYNDROME FOR WHOM

RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%

RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Recordati Rare Diseases annonce la publication dans The Journal of Clinical Endocrinology & Metabolism des résultats de l’étude de Phase III LINC 4 confirmant l'efficacité et la tolérance d’Isturisa® (osilodrostat)...

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

RECORDATI: TO BE HIGHLIGHTED AT AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY (AACE) ANNUAL MEETING--THE EXPANDED INDICATION FOR ISTURISA® (OSILODROSTAT) FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN ADULT PATIENTS WITH CUSHING'S SYNDROME FOR WHOM

RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%

RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

REC - Frequently Asked Questions (FAQ)

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Recordati SpA (REC) 시세

Recordati SpA (REC)

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

주요 통계 및 세부정보

Recordati SpA 정보

REC 최신 뉴스

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

RECORDATI: TO BE HIGHLIGHTED AT AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY (AACE) ANNUAL MEETING--THE EXPANDED INDICATION FOR ISTURISA® (OSILODROSTAT) FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN ADULT PATIENTS WITH CUSHING'S SYNDROME FOR WHOM

RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%

RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Recordati Rare Diseases annonce la publication dans The Journal of Clinical Endocrinology & Metabolism des résultats de l’étude de Phase III LINC 4 confirmant l'efficacité et la tolérance d’Isturisa® (osilodrostat)...

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

RECORDATI: TO BE HIGHLIGHTED AT AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY (AACE) ANNUAL MEETING--THE EXPANDED INDICATION FOR ISTURISA® (OSILODROSTAT) FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN ADULT PATIENTS WITH CUSHING'S SYNDROME FOR WHOM

RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%

RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

REC - Frequently Asked Questions (FAQ)

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

로그인

광고 제거